# What Happened to the Research Peptide Vendors That Closed in 2025–2026?
Between mid-2025 and mid-2026, the research peptide industry experienced a massive structural shift. At least nine major suppliers abruptly ceased operations, leaving thousands of independent researchers and laboratories without their primary source for compounds.
The closures included some of the highest-volume vendors in the space, most notably Peptide Sciences (which closed its doors in March 2026), alongside Science.bio, Amino Asylum, Paradigm Peptides, and several others.
For researchers scrambling to re-establish reliable supply chains, understanding *why* these closures happened is less important than understanding *how to evaluate* the vendors that remain. The market contraction has flooded the space with new, unverified suppliers attempting to capture displaced demand.
This guide explains the current state of the research peptide market and provides a strict framework for evaluating new suppliers based on documentation, transparency, and analytical testing standards.
## The 2025–2026 Market Contraction
The wave of closures affected vendors of all sizes, but the most significant impact came from the shutdown of legacy suppliers that had operated for years. While the specific reasons for each closure varied—ranging from regulatory pressure and payment processing challenges to supply chain disruptions—the net result was a sudden vacuum in the market.
Researchers who had relied on established relationships with a single vendor found themselves forced to navigate a market that had become significantly more opaque. The sudden influx of buyers searching for “Peptide Sciences alternatives” or “where to buy BPC-157” created an environment ripe for exploitation by vendors cutting corners on quality control.
## The New Standard: Documentation Over Reputation
Prior to 2025, many researchers relied on vendor reputation, Reddit reviews, or forum consensus to select suppliers. In the post-2026 landscape, reputation is no longer a sufficient proxy for purity. The only reliable metric is independent, verifiable documentation.
When evaluating a new supplier, researchers must apply a strict, zero-trust framework based entirely on analytical testing.
### 1. Mandatory Third-Party Testing
A vendor claiming “99% purity” is meaningless without independent verification. The standard for research-grade peptides requires testing by an accredited, third-party analytical laboratory.
**What to look for:**
* **Published Certificates of Analysis (COAs):** The vendor must publish the actual lab report, not just a summary graphic.
* **Batch-Specific Testing:** A COA from 2024 is irrelevant for a batch sold in 2026. Testing must be tied to the specific batch currently in stock.
* **Independent Laboratories:** The testing must be performed by a recognized, independent facility (e.g., MZ Biolabs, Janoshik, Colmaric, or Freedom Diagnostics), not an “in-house” lab.
### 2. The Required Analytical Panel
A proper COA must confirm three distinct metrics. If any of these are missing, the documentation is incomplete.
| Metric | Testing Method | Why It Matters |
|——–|—————-|—————-|
| **Purity** | High-Performance Liquid Chromatography (HPLC) | Confirms the percentage of the sample that is the target peptide versus impurities or synthesis byproducts. The standard is ≥99%. |
| **Identity** | Liquid Chromatography-Mass Spectrometry (LC-MS) | Confirms the molecular weight matches the target peptide exactly. HPLC alone cannot prove identity; it only proves purity of *something*. |
| **Net Content** | Quantitative Analysis | Confirms the vial actually contains the stated mass (e.g., exactly 10mg), not just a pure sample of a smaller amount. |
### 3. Verification and Transparency
The best vendors make verification effortless. The COA should include a reference number or batch ID that can be cross-referenced directly with the testing laboratory. If a vendor obscures the lab’s contact information or redacts the batch numbers, it is a red flag.
## The Full Scale Peptides Approach
At Full Scale Peptides, our operational model was built specifically to address the opacity of the legacy peptide market. We operate under a strict transparency mandate that aligns with the highest requirements of institutional researchers.
* **Every Batch Tested:** We do not sell a single vial without a corresponding, batch-specific COA.
* **Published Results:** All COAs are published openly in our [COA Library](/coa/)—no purchase or signup required to view them.
* **Comprehensive Panels:** Our testing protocol through Freedom Diagnostics includes both HPLC for purity (guaranteed ≥99%) and mass spectrometry for identity.
* **U.S. Operations:** As a First Responder owned and operated company, we maintain strict chain-of-custody and ship same-day from the United States.
The closure of legacy vendors disrupted the market, but it also forced a necessary evolution. The era of blind trust in peptide suppliers is over. The new standard is absolute transparency, verified by independent data.
***
*Disclaimer: All products sold by Full Scale Peptides are strictly for laboratory research use only. They are not intended for human or veterinary consumption, diagnostic, or therapeutic use.*